@entity548 complications associated with the use of intravenous tissue plasminogen activator in treatment of XXXX .

@entity1 @entity2002 @entity101 @entity548 @entity510 @entity190 @entity1410 @entity2480 @entity2333 @entity583 @entity360
PURPOSE: Little attention has been paid to the importance of clinical factors associated with @entity548 complications caused by the use of thrombolytic agents. The goal of our study was to examine clinical and hematologic factors associated with an increased risk of @entity548 in a prospectively observed population that received intravenous tissue plasminogen activator for @entity583 . @entity1 AND METHODS: Bleeding complications were evaluated in 386 consecutive @entity1 treated with 150 mg of tissue plasminogen activator over six to eight hours for @entity583 . All @entity1 also underwent immediate cardiac catheterization. RESULTS: Quantitation of @entity190 during the @entity1 ' hospital stay included a median drop in hematocrit of 11.4 points, a median nadir hematocrit of 31.2, a 14 percent rate of significant clinically evident @entity548 , and a 31 percent rate of transfusion of two or more units of blood. All of these parameters were much more severe in @entity1 treated with coronary artery bypass surgery. Access site @entity1410 was the most common source of @entity548 (45 percent of @entity1 ), whereas 8 percent had @entity360 , two @entity1 had @entity548 , and two @entity1 had @entity510 . The median nadir @entity2002 was 1.3 g/liter. Multiple linear regression models were used to investigate the relationship between clinical variables, including multiple hematologic measurements, and measures of the amount of @entity190 . The use of coronary artery bypass grafting was the variable most closely associated with @entity548 . Other invasive procedures (angioplasty and @entity2333 ) were also associated with increased @entity548 . Among the @entity1 descriptors examined, lighter weight, older age, female sex, and history of @entity101 were associated with greater @entity190 . Of @entity2480 parameters, only nadir @entity2002 levels were significantly associated with more @entity548 . CONCLUSION: Careful clinical evaluation may improve assessment of the risk/benefit ratio of thrombolytic therapy.
